ReviewOpen biology2016
High-throughput recombinant protein expression in Escherichia coli: current status and future perspectives.
Review in Open biology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 129 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
129 citing papers in PubMed.
- A generalizable method for the purification and biophysical characterization of bacterial membrane receptors.Protein science : a publication of the Protein Society · 2026Article
- From gene to enzyme: Microbial engineering of bovine chymosin for efficient cheese coagulation.World journal of microbiology & biotechnology · 2026Article
- Integrating multimodal features with deep learning for protein solubility prediction.Journal of cheminformatics · 2026Article
- Low inducer concentrations at 10 °C promotes soluble recombinant expression of Aedes aegypti mosquito midgut proteases in E. coli.Microbial cell factories · 2026Article
- Expression, Solubilization, and Refolding Recovery of a Novel l‑Asparaginase-Arginase 1 Chimera fromACS omega · 2026Article
- Biochemical Engineering Perspective on cGAS: From Enzyme Discovery to Potential Industrial Application.Chembiochem : a European journal of chemical biology · 2026Review
- Engineered Escherichia coli as a microbial cell factory for intracellular protein delivery: strains, vectors, mechanisms, and therapeutic applications.Microbial cell factories · 2026Review
- Production of Novel Thermostable Esterases fromInternational journal of molecular sciences · 2026Article
- Development of an Indirect ELISA for REV gp90 Antibody Detection Using the gp90 Protein Expressed in Suspended Cells.Viruses · 2026Article
- A novel recombinant oligogalacturonide lyase fromFrontiers in bioengineering and biotechnology · 2026Article
- Article
- Proteolytic Activities and Immunological Effects of Light Chains of Botulinum Neurotoxin A1, A2 and A3 Subtypes.Toxins · 2025Article
- Low Inducer Concentrations at 10°C Promotes Soluble Recombinant Expression of Aedes aegypti Mosquito Midgut Proteases in E. coli.Research square · 2025Article
- Recombinant Expression and Bioprocess Optimization of Priestia megaterium α-Amylase and Its Impact on Dough Fermentation Efficiency.Chemistry & biodiversity · 2025Article
- A Simple and Cost-Efficient Method for the Production of Recombinant Horseradish Peroxidase in E. coli.Molecular biotechnology · 2025Article
- A High-Throughput Multi Well Plate-Based Approach for the Combined Expression, Export, and Assay of Recombinant Proteins.Current protocols · 2025Article
- Isolation and identification of the lactase (β-galactosidase) from the soil bacteriumFood science and biotechnology · 2025Article
- Development of a time-resolved fluorescence immunochromatographic strip for gB antibody detection of PRV.BMC veterinary research · 2025Article
- Pattern of sensitization to yellow jacket venom and expression of recombinant antigen 5 (Ves v 5) from yellow jacket venom.BMC immunology · 2025Article
- Article
69 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The ease of genetic manipulation, low cost, rapid growth and number of previous studies have made Escherichia coli one of the most widely used microorganism species for producing recombinant proteins. In this post-genomic era, challenges remain to rapidly express and purify large numbers of proteins for academic and commercial purposes in a high-throughput manner. In this review, we describe several state-of-the-art approaches that are suitable for the cloning, expression and purification, conducted in parallel, of numerous molecules, and we discuss recent progress related to soluble protein expression, mRNA folding, fusion tags, post-translational modification and production of membrane proteins. Moreover, we address the ongoing efforts to overcome various challenges faced in protein expression in E. coli, which could lead to an improvement of the current system from trial and error to a predictable and rational design.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.